Compare Eli Lilly And Co (LLY) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Schwab US Large Cap Growth ETF — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Schwab US Large Cap Growth ETF trades at $36.74 (market cap $65.01B). The key difference: Eli Lilly And Co is far larger — about 16× Schwab US Large Cap Growth ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while Schwab US Large Cap Growth ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Schwab US Large Cap Growth ETF for 50 Days on average.
| LLY | SCHG | |
|---|---|---|
Market Cap | $1.04T | $65.01B |
Volume | 3,064,878 | 8,554,399 |
Sector | Health | Sector/Thematic |
52-Week High | $1.28K | $36.93 |
52-Week Low | $799.57 | $28.10 |
Typical Hold Time | 93 Days | 50 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company's weight-loss drug portfolio continues to drive exceptional performance, with Q2 2026 EPS of $8.38 beating expectations by 31%. Technical indicators show bullish moving averages while fundamentals reveal impressive 83.4% gross margins and 102.44% ROE. Recent clinical trial successes for next-generation obesity treatments position Lilly for continued market leadership.
LLY presents a compelling growth story with dominant positioning in the expanding obesity/diabetes market, though elevated valuations (P/E 39.26) and regulatory risks require monitoring. Analyst consensus remains strongly bullish with $1,350 price target representing 15% upside. The primary investment thesis centers on pipeline execution and market expansion opportunities, balanced against competitive pressures and valuation concerns.
SCHG (Schwab U.S. Large-Cap Growth ETF) trades at $36.42, down 1.22% with a bullish technical signal from moving averages. The ETF focuses on large-cap growth stocks with heavy concentration in top holdings like Apple. Recent news highlights SCHG's long-term growth potential and tax-efficient characteristics for retirement planning.
SCHG offers exposure to quality growth companies at a low 0.03% expense ratio, but faces concentration risk in top holdings. The ETF's performance depends heavily on megacap tech stocks, making it vulnerable to sector rotations. Long-term growth prospects remain strong based on historical performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
